ArticleBMC infectious diseases2026
Prognostic value of dynamic procalcitonin (PCT-Δ) for adverse outcomes in patients with pyogenic liver abscess: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterize the clinical profile of pyogenic liver abscess (PLA) complicated by sepsis and investigate the prognostic value of dynamic Procalcitonin (PCT-Δ, peak-to-trough difference) for adverse outcomes (primary: death, multiple organ dysfunction syndrome [MODS]; secondary: hospital stay > 14 days) in PLA patients, and to analyze its non-linear association with adverse outcomes.
methodsThis retrospective cohort study enrolled 170 consecutive PLA patients at a tertiary hospital in Guangzhou (January 2020–December 2024). Sepsis was defined per Sepsis-3 criteria (infection + acute organ dysfunction, SOFA score increment ≥ 2 or absolute score > 2) and was assessed throughout hospitalization. Clinical/laboratory data, including PCT levels at admission, peak, and trough during hospitalization, were collected. Restricted cubic spline (RCS) analysis with 3 knots explored non-linear associations between PCT-Δ and adverse outcomes. Receiver operating characteristic (ROC) curves with 1000-iteration bootstrap resampling and calibration curves evaluated the prognostic performance of PCT-Δ, with multivariable logistic regression models adjusted for sex, age, diabetes, biliary disease, malignancy, and abscess size.
resultsOf 170 patients, 72 (42.35%) developed sepsis during hospitalization. The cohort had a median age of 61 years (IQR 51.0–70.0) with male predominance (67.60%). PCT-Δ (median 30.03 vs. 1.28 ng/mL, P < 0.001) was significantly higher in PLA patients with adverse outcomes. RCS analysis revealed a significant non-linear relationship between PCT-Δ and adverse outcomes (P-overall < 0.001, P-nonlinear = 0.002): the risk of adverse outcomes rose rapidly when PCT-Δ was 0–50 ng/mL and slowed above 50 ng/mL. ROC analysis showed robust prognostic performance: Model 1 (PCT-Δ alone) AUC = 0.833 (95% CI: 0.771–0.895); Model 2 (adjusted for covariates) AUC = 0.843 (95% CI: 0.784–0.902). Bootstrap validation yielded a corrected C-statistic of 0.834 (AUC SD = 0.0423), with calibration curves showing excellent agreement between predicted and observed probabilities.
conclusionSepsis complicating PLA is associated with poor outcomes. PCT-Δ is significantly non-linearly associated with adverse outcomes in PLA patients and has good prognostic value for this population. This dynamic biomarker may assist clinicians in risk stratification of PLA patients, particularly those with complicated sepsis. However, the application of PCT-Δ is limited by its time window of measurement, and prospective multicenter validation is needed to confirm its clinical utility. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.